Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 3Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Antibodies, Bispecific × Gynecologic × Clear all
NCT03030287 2020-09-03

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Mereo BioPharma

Phase 1 Completed
44 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡